PFE · NYSE
PFE · NYSE
30.45 USD
+0.50 (+1.65%)
No new catalyst. Pfizer continued to rise with large-pharma peers, led by sharp gains in AstraZeneca, Merck, and Bristol Myers, while the broader equity market sold off. The earlier broad pharma buying remained the driver; Pfizer's India plant outage report was a negative company development rather than the cause of the gain. source
No new catalyst. Pfizer continued to rise with large-pharma peers, led by sharp gains in AstraZeneca, Merck, and Bristol Myers, while the broader equity market sold off. The earlier broad pharma buying remained the driver; Pfizer's India plant outage report was a negative company development rather than the cause of the gain. source